172 related articles for article (PubMed ID: 24024162)
1. Thioredoxin interacting protein and its association with clinical outcome in gastro-oesophageal adenocarcinoma.
Woolston CM; Madhusudan S; Soomro IN; Lobo DN; Reece-Smith AM; Parsons SL; Martin SG
Redox Biol; 2013; 1(1):285-91. PubMed ID: 24024162
[TBL] [Abstract][Full Text] [Related]
2. Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas.
Bain GH; Collie-Duguid E; Murray GI; Gilbert FJ; Denison A; McKiddie F; Ahearn T; Fleming I; Leeds J; Phull P; Park K; Nanthakumaran S; Matula KM; Grabsch HI; Tan P; Welch A; Schweiger L; Dahle-Smith A; Urquhart G; Finegan M; Petty RD
Br J Cancer; 2014 Mar; 110(6):1525-34. PubMed ID: 24569475
[TBL] [Abstract][Full Text] [Related]
3. Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy.
Fareed KR; Al-Attar A; Soomro IN; Kaye PV; Patel J; Lobo DN; Parsons SL; Madhusudan S
Br J Cancer; 2010 May; 102(11):1600-7. PubMed ID: 20461087
[TBL] [Abstract][Full Text] [Related]
4. Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma.
Borg D; Larsson AH; Hedner C; Nodin B; Johnsson A; Jirström K
J Transl Med; 2018 Oct; 16(1):290. PubMed ID: 30355278
[TBL] [Abstract][Full Text] [Related]
5. Caspase-cleaved cytokeratin-18 and tumour regression in gastro-oesophageal adenocarcinomas treated with neoadjuvant chemotherapy.
Fareed KR; Soomro IN; Hameed K; Arora A; Lobo DN; Parsons SL; Madhusudan S
World J Gastroenterol; 2012 Apr; 18(16):1915-20. PubMed ID: 22563171
[TBL] [Abstract][Full Text] [Related]
6. Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy.
Fareed KR; Ilyas M; Kaye PV; Soomro IN; Lobo DN; Parsons SL; Madhusudan S
Histopathology; 2009 Oct; 55(4):399-406. PubMed ID: 19817890
[TBL] [Abstract][Full Text] [Related]
7. Significance of tumour regression in lymph node metastases of gastric and gastro-oesophageal junction adenocarcinomas.
Reim D; Novotny A; Friess H; Slotta-Huspenina J; Weichert W; Ott K; Dislich B; Lorenzen S; Becker K; Langer R
J Pathol Clin Res; 2020 Oct; 6(4):263-272. PubMed ID: 32401432
[TBL] [Abstract][Full Text] [Related]
8. Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma.
Geh JI; Glynne-Jones R; Kwok QS; Banerji U; Livingstone JI; Townsend ER; Harrison RA; Mitchell IC
Clin Oncol (R Coll Radiol); 2000; 12(3):182-7. PubMed ID: 10942336
[TBL] [Abstract][Full Text] [Related]
9. [Preliminary results of neoadjuvant treatment of adenocarcinoma of the gastro-esophageal junction].
Pedrazzani C; Pasini F; Giacopuzzi S; Bernini M; Gabbani M; Grandinetti A; Tomezzoli A; Ruzzenente A; Guglielmi A; de Manzoni G
Chir Ital; 2005; 57(1):9-14. PubMed ID: 15832733
[TBL] [Abstract][Full Text] [Related]
10. Histopathologic Features are more Important Prognostic Factors than Primary Tumour Location in Gastro-oesophageal Adenocarcinoma Treated with Preoperative Chemoradiation and Surgery.
Vošmik M; Laco J; Sirák I; Dvořák J; Lochman P; Hodek M; Malá P; Rejchrt S; Repák R; Leško M; Ferko A; Ryška A; Melichar B; Petera J
Pathol Oncol Res; 2018 Apr; 24(2):373-383. PubMed ID: 28550507
[TBL] [Abstract][Full Text] [Related]
11. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
[TBL] [Abstract][Full Text] [Related]
12. Paradoxical clinical deterioration despite near-complete pathological response to neoadjuvant chemotherapy for locally advanced gastro-oesophageal adenocarcinoma.
Windsor AC; Somers SS; Crellin A; Hassan S; Macadam R; Sadek SA; Guillou PJ; Reynolds JV
Surg Oncol; 1995; 4(5):277-9. PubMed ID: 8850030
[TBL] [Abstract][Full Text] [Related]
13. Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: a GERCOR study.
Watson S; Validire P; Cervera P; Zorkani N; Scriva A; Lemay F; Tournigand C; Perniceni T; Garcia ML; Bennamoun M; Paye F; Louvet C
Ann Oncol; 2013 Dec; 24(12):3035-9. PubMed ID: 24114855
[TBL] [Abstract][Full Text] [Related]
14. High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients.
Langer R; Ott K; Feith M; Lordick F; Specht K; Becker K; Hofler H
J Surg Oncol; 2010 Oct; 102(5):503-8. PubMed ID: 20589706
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma.
Mackay HJ; McInnes A; Paul J; Raby N; Lofts FJ; McDonald AC; Soukop M; Fullarton GM; Harris AL; Garcia-Vargas J; Evans TR
Ann Oncol; 2001 Oct; 12(10):1407-10. PubMed ID: 11762812
[TBL] [Abstract][Full Text] [Related]
16. Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment.
Hedner C; Borg D; Nodin B; Karnevi E; Jirström K; Eberhard J
J Clin Pathol; 2018 May; 71(5):451-462. PubMed ID: 29138285
[TBL] [Abstract][Full Text] [Related]
17. Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer.
Melcher AA; Mort D; Maughan TS
Br J Cancer; 1996 Nov; 74(10):1651-4. PubMed ID: 8932350
[TBL] [Abstract][Full Text] [Related]
18. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
19. Expression of the calpain system is associated with poor clinical outcome in gastro-oesophageal adenocarcinomas.
Storr SJ; Pu X; Davis J; Lobo D; Reece-Smith AM; Parsons SL; Madhusudan S; Martin SG
J Gastroenterol; 2013 Nov; 48(11):1213-21. PubMed ID: 23329366
[TBL] [Abstract][Full Text] [Related]
20. High PTGS2 expression in post-neoadjuvant chemotherapy-treated oesophageal adenocarcinoma is associated with improved survival: a population-based cohort study.
Spence AD; Trainor J; McMenamin Ú; Turkington RC; McQuaid S; Bingham V; James J; Salto-Tellez M; McManus DT; Johnston BT; Cardwell CR; Coleman HG
Histopathology; 2019 Mar; 74(4):587-596. PubMed ID: 30408225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
